Morgan Stanley’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-39,631
Closed -$2.37M – 6928
2020
Q2
$2.37M Buy
39,631
+37,609
+1,860% +$2.32M ﹤0.01% 3440
2020
Q1
$120K Sell
2,022
-58,987
-97% -$3.44M ﹤0.01% 5111
2019
Q4
$3.34M Sell
61,009
-56,863
-48% -$2.12M ﹤0.01% 3615
2019
Q3
$3.33M Buy
117,872
+84,312
+251% +$3.09M ﹤0.01% 3314
2019
Q2
$1.11M Buy
33,560
+31,689
+1,694% +$989K ﹤0.01% 4160
2019
Q1
$64K Sell
1,871
-6,856
-79% -$218K ﹤0.01% 5560
2018
Q4
$239K Buy
8,727
+4,516
+107% +$116K ﹤0.01% 5213
2018
Q3
$123K Buy
+4,211
New +$119K ﹤0.01% 5626

Other funds holding PRNB

Morgan Stanley's PRNB Position: Q3 2020 in Review

Morgan Stanley sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 39,631 shares — an estimated $2.37M sold.

Morgan Stanley first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $3.34M in Q4 2019. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • Morgan Stanley reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Morgan Stanley sold 39,631 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $2.37M.
  • Morgan Stanley first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • Morgan Stanley's Principia Biopharma Inc. Common Stock position peaked at $3.34M in Q4 2019.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Morgan Stanley's 13F filing for Q3 2020, filed 13 Nov 2020.